Ticker
ABUS

Price
2.31
Stock movement down
-0.01 (-0.43%)
Company name
Arbutus Biopharma Corp
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
343.56M
Ent value
333.26M
Price/Sales
16.01
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
0.10%
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-29.14%
3 year return
19.31%
5 year return
-8.99%
10 year return
-4.26%
Last updated: 2022-08-25

DIVIDENDS

ABUS does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF0.02
Price to FCF0.02
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales16.01
Price to Book-
EV to Sales15.53

FINANCIALS

Per share

Loading...
Per share data
Current share count148.73M
EPS (TTM)-0.75
FCF per share (TTM)203.07

Income statement

Loading...
Income statement data
Revenue (TTM)21.46M
Gross profit (TTM)8.88M
Operating income (TTM)-68.82M
Net income (TTM)-75.63M
EPS (TTM)-0.75
EPS (1y forward)-0.62

Margins

Loading...
Margins data
Gross margin (TTM)41.36%
Operating margin (TTM)-320.75%
Profit margin (TTM)-352.49%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash81.33M
Net receivables1.31M
Total current assets172.70M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets236.88M
Accounts payable1.19M
Short/Current long term debt2.54M
Total current liabilities32.41M
Total liabilities71.03M
Shareholder's equity0.00
Net tangible assets165.84M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)20.57B
Capital expenditures (TTM)710.00K
Free cash flow (TTM)20.57B
Dividends paid (TTM)20.44M

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-
Return on Invested Capital-
Cash Return on Invested Capital-

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.32
Daily high2.40
Daily low2.27
Daily Volume410K
All-time high30.94
1y analyst estimate6.50
Beta2.44
EPS (TTM)-0.75
Dividend per share-
Ex-div date-
Next earnings date2 Nov 2022

Downside potential

Loading...
Downside potential data
ABUSS&P500
Current price drop from All-time high-92.53%-12.18%
Highest price drop-97.19%-56.47%
Date of highest drop9 Oct 20199 Mar 2009
Avg drop from high-70.87%-11.38%
Avg time to new high110 days12 days
Max time to new high2132 days1805 days
COMPANY DETAILS
ABUS (Arbutus Biopharma Corp) company logo
Marketcap
343.56M
Marketcap category
Small-cap
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Employees
85
Investor relations
-
SEC filings
CEO
William H. Collier
Country
USA
City
Warminster
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove...
September 22, 2022
WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove...
September 6, 2022
Every investor in Arbutus Biopharma Corporation ( NASDAQ:ABUS ) should be aware of the most powerful shareholder...
September 6, 2022
The patent is expected to provide the company with exclusivity for its experimental RNAi therapeutic until at least April 2038.
September 1, 2022
WARMINSTER, Pa., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel...
August 30, 2022
The Cambridge company (Nasdaq: MRNA) alleged in a complaint filed in the U.S. District Court of Massachusetts Friday that Pfizer (NYSE: PFE) and BioNTech's vaccine, Comirnaty, violates three patents M...
August 26, 2022
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...
August 10, 2022
At this time, I would like to welcome everyone to the Arbutus Biopharma 2022 second quarter financial results and corporate update. Good morning, everyone, and thank you for joining our second quarte...
August 4, 2022
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
August 4, 2022
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call ...
August 4, 2022
Next page